Why Lewy body dementia is the most frequently misdiagnosed form of cognitive decline

Health · Published 30 September 2026 Swipe more like this →

In short: Dementia with Lewy bodies is the second most common form of dementia after Alzheimer's, yet it remains widely misunderstood. Characterized by protein clumps in the brain, it presents a complex array of symptoms—from visual hallucinations to movement disorders—that often lead to clinical confusion and delayed, accurate diagnosis.

Dementia with Lewy bodies (DLB) is a neurodegenerative condition driven by the accumulation of abnormal protein deposits known as Lewy bodies within brain cells. These deposits, which are also found in Parkinson's disease, disrupt normal signaling between neurons. While the exact cause of this aggregation remains unclear, researchers believe these proteins interfere with critical brain functions, including visual perception, muscle control, and cognitive processing. Unlike Alzheimer's disease, where memory loss is often the primary indicator, DLB frequently manifests through fluctuating alertness, vivid hallucinations, and parkinsonian motor symptoms like tremors or stiff limbs.

The clinical overlap between DLB, Parkinson's disease, and Alzheimer's creates a significant diagnostic challenge. As of 2014, Lewy body dementias were more frequently misdiagnosed than any other common form of dementia. Distinguishing between these conditions is vital; for instance, individuals with DLB often exhibit a severe sensitivity to antipsychotic medications, making an incorrect diagnosis potentially dangerous. Currently, there is no single definitive test for the condition. Diagnosis relies on a combination of symptom assessment, cognitive testing, and neuroimaging, such as MRI or SPECT scans, to rule out other pathologies.

Recent scientific efforts are turning toward biomarkers to improve diagnostic precision. Exploratory studies using plasma microRNA models and proteomic profiling have shown promise in differentiating DLB from Alzheimer's and Parkinson's. By analyzing specific protein signatures or RNA markers, researchers hope to move beyond subjective clinical assessments toward objective, biological verification. While these advancements are encouraging, they are largely in the pilot stage. For patients, the outlook remains variable, with an average survival time of five to seven years post-diagnosis, though this timeline is highly individual. Management currently focuses on symptom control through a mix of medication, physical therapy, and cognitive stimulation, as no cure or disease-slowing treatment exists.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Dementia with Lewy bodies is a complex neurodegenerative condition often misdiagnosed as Alzheimer's disease.
• Parkinson’s erodes dopamine cells that start and smooth movement
• Dementia is not normal aging—even past age ninety
• The Parkinson's lookalike whose damage hides in the brain's support cells
• Parkinsonism is a broad clinical syndrome, not just the disease that shares its name.
• Why did humans evolve light skin? It is not just about the cold.
• Levofloxacin is a powerful antibiotic, but its use carries risks that demand careful consideration.
• Neuroscientists still argue over which parts make up the limbic system
• Leukemia is the most common cancer in children
• Limerick once ran its own soviet, printing money for twelve days
• Leucine is the essential amino acid that acts as a master switch for muscle.
• Linezolid is a powerful antibiotic, but it must be used as a last resort.

More in Health, medicine and disease · More in Health · Latest · A–Z · All topics